Technical Analysis for KZIA - Kazia Therapeutics Limited

Grade Last Price % Change Price Change
F 0.23 3.84% 0.01
KZIA closed up 3.84 percent on Monday, March 18, 2024, on 26 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
MACD Bullish Signal Line Cross Bullish 3.84%
Narrow Range Bar Range Contraction 3.84%
Wide Bands Range Expansion 3.84%
1,2,3 Retracement Bearish Bearish Swing Setup 4.07%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.07%
Narrow Range Bar Range Contraction 4.07%
Wide Bands Range Expansion 4.07%
Oversold Stochastic Weakness 4.07%

   Recent Intraday Alerts

Alert Time
Up 5% about 13 hours ago
Up 3% about 13 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Rose Above Previous Day's High about 15 hours ago
Down 1% about 15 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kazia Therapeutics Limited Description

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Cancer Treatment ATM Chemotherapy Ovarian Cancer Blastoma Cancer Cell Glioma Neuroblastoma Cytoskeleton Diffuse Intrinsic Pontine Glioma Novogen Pharmaceutical Research

Is KZIA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.68
52 Week Low 0.1866
Average Volume 886,214
200-Day Moving Average 0.71
50-Day Moving Average 0.29
20-Day Moving Average 0.25
10-Day Moving Average 0.22
Average True Range 0.04
RSI (14) 41.86
ADX 29.37
+DI 12.66
-DI 19.47
Chandelier Exit (Long, 3 ATRs) 0.34
Chandelier Exit (Short, 3 ATRs) 0.30
Upper Bollinger Bands 0.35
Lower Bollinger Band 0.16
Percent B (%b) 0.38
BandWidth 75.18
MACD Line -0.03
MACD Signal Line -0.03
MACD Histogram 0.0018
Fundamentals Value
Market Cap 6.13 Million
Num Shares 26.4 Million
EPS -0.73
Price-to-Earnings (P/E) Ratio -0.32
Price-to-Sales 12881.51
Price-to-Book 0.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.26
Resistance 3 (R3) 0.26 0.25 0.25
Resistance 2 (R2) 0.25 0.24 0.25 0.25
Resistance 1 (R1) 0.24 0.24 0.24 0.24 0.25
Pivot Point 0.23 0.23 0.23 0.23 0.23
Support 1 (S1) 0.22 0.22 0.23 0.22 0.21
Support 2 (S2) 0.21 0.22 0.21 0.21
Support 3 (S3) 0.21 0.21 0.21
Support 4 (S4) 0.21